Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469478 | 0.79 | MAOB (0.39) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL15469471 | 0.79 | MAOB (0.39) | MAOBMAOAKMT2AGRM5NPC1 | |
| SCHEMBL18479447 | 0.79 | ADRA2A (0.31) | KMT2ANPC1RAB9A | |
| SCHEMBL23782777 | 0.79 | MAOB (0.39) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL15070849 | 0.79 | MAOB (0.34) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL15469485 | 0.79 | MAOB (0.39) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL2669099 | 0.76 | ALDH1A1 (0.41) | KMT2AGRM5ALDH1A1HPGD | |
| SCHEMBL2669710 | 0.74 | GRM5 (0.40) | KMT2AGRM5 | |
| SCHEMBL31168610 | 0.74 | PKM (0.34) | MAOBKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL827778 | 0.74 | PKM (0.34) | MAOBKMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392397-B2 | Heterocyclic thiosemicarbazone derivatives and their therapeutical applications | NANTBIO, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC | 2018-07-26 | — | — | US | disclosed |
| WO-2017024315-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | MAOB 1631/4885MAOA 601/4885KMT2A 2639/4885 |
| US-10392397-B2 | Heterocyclic thiosemicarbazone derivatives and their therapeutical applications | TPMT, MKI67, TST | MAOB 509/4885MAOA 1773/4885KMT2A 3192/4885 |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | TPMT, MKI67, TST | MAOB 509/4885MAOA 1773/4885KMT2A 3192/4885 |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | MAOB 1631/4885MAOA 601/4885KMT2A 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.